In this report, the Global Endobronchial Ultrasound Biopsy Market has been segmented by Product, Type, Application, End-user and Geography.

Global Endobronchial Ultrasound Biopsy Market, Segmentation by Product

The Global Endobronchial Ultrasound Biopsy Market has been segmented by Product into Biopsy Forceps, Cytology Brushes, Biopsy Needles, Transbronchial Aspiration Needles, Spray Catheters, and Others.

Biopsy Forceps
Biopsy forceps lead the EBUS biopsy product category with a market share of about 25%, offering a reliable tool for extracting lung and lymph node tissue during bronchoscopy. These forceps are widely used in diagnosing lung cancer, sarcoidosis, and other pulmonary lesions, thanks to their precise grip, durability, and compatibility with modern flexible bronchoscopes.

Cytology Brushes
Cytology brushes comprise nearly 18% of the market and are critical for collecting superficial epithelial cells. They are frequently used to evaluate airway abnormalities, such as tumors and infections, offering a non-invasive and cost-effective method for initial cytologic screening in both inpatient and outpatient settings.

Biopsy Needles
Biopsy needles represent about 20% of the market and are used for fine-needle aspiration (FNA) under endobronchial ultrasound guidance. Their high yield in sampling peripheral lung lesions and central masses makes them indispensable for oncologic and infectious disease diagnostics.

Transbronchial Aspiration Needles
Transbronchial aspiration needles, accounting for around 15%, are key components in EBUS-TBNA procedures, the gold standard for lung cancer staging and lymph node sampling. Their use has expanded rapidly due to increasing demand for minimally invasive mediastinal access.

Spray Catheters
Spray catheters contribute roughly 12% to the market and are used to deliver topical anesthesia or diagnostic agents to targeted airway regions. These devices improve patient comfort, reduce procedure time, and support multi-instrument workflows in EBUS settings.

Others
The Others category, making up about 10%, includes a range of supporting devices like suction catheters, tissue collection traps, and accessory cleaning tools. These are vital for maintaining a sterile field, sample integrity, and operational efficiency during diagnostic bronchoscopy.

Global Endobronchial Ultrasound Biopsy Market, Segmentation by Type

The Global Endobronchial Ultrasound Biopsy Market has been segmented by Type into Radial Probe Endobronchial Ultrasound and Convex Probe Endobronchial Ultrasound.

Radial Probe Endobronchial Ultrasound
Radial probe EBUS comprises about 35% of the global EBUS biopsy market and is widely used for the evaluation of peripheral lung lesions. This technique utilizes a 360-degree ultrasound view to locate abnormal tissues deep within the lungs. While it lacks real-time needle visualization, it is often used in combination with fluoroscopy and guide sheaths to perform targeted biopsies, especially in early-stage or small-size pulmonary nodules.

Convex Probe Endobronchial Ultrasound
Convex probe EBUS leads the market with an estimated 65% share and is considered the gold standard for mediastinal lymph node sampling. It supports real-time needle guidance during EBUS-TBNA procedures, significantly enhancing the accuracy of lung cancer diagnosis and staging. Its dual function as both an ultrasound imaging tool and a biopsy platform makes it indispensable in advanced pulmonary and thoracic oncology.

Global Endobronchial Ultrasound Biopsy Market, Segmentation by Application

The Global Endobronchial Ultrasound Biopsy Market has been segmented by Application into Cancer Diagnosis, Infection Diagnosis, and Others.

Cancer Diagnosis
Cancer diagnosis is the leading application of EBUS biopsy, accounting for nearly 68% of the global market. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has become the gold standard for lung cancer staging, offering accurate assessment of mediastinal and hilar lymph nodes. With increasing incidence of non-small cell lung cancer, the demand for minimally invasive, real-time diagnostic procedures continues to rise in both developed and emerging markets.

Infection Diagnosis
Infection diagnosis comprises around 22% of the market, with EBUS playing a crucial role in diagnosing tuberculosis, fungal infections, and sarcoidosis involving the thoracic lymph nodes. The technique provides access to deep thoracic structures without surgery, enhancing diagnosis of atypical infections and chronic inflammatory conditions, especially in resource-constrained healthcare systems.

Others
The Others category contributes approximately 10%, encompassing EBUS use in lymphoma assessment, autoimmune disease evaluation, and cases of unexplained lymphadenopathy. As EBUS becomes more integrated into interdisciplinary diagnostic protocols, its scope is expanding beyond oncology into broader respiratory and immune system diagnostics.

Global Endobronchial Ultrasound Biopsy Market, Segmentation by End-user

The Global Endobronchial Ultrasound Biopsy Market has been segmented by End-user into Hospitals, Ambulatory Surgical Centers, Cancer Specialty Clinics and Diagnostics Centers.

Hospitals
Hospitals dominate the global EBUS biopsy market with nearly 50% share, driven by their role as centers for comprehensive pulmonary diagnostics and advanced thoracic procedures. Equipped with interventional suites, trained bronchoscopists, and oncology departments, hospitals are the primary choice for patients requiring EBUS-guided lymph node evaluation and lung cancer staging. Their ability to integrate multimodal diagnostic workflows makes them essential to market growth.

Ambulatory Surgical Centers
Ambulatory surgical centers (ASCs) hold about 20% of the market, offering minimally invasive diagnostic services in a more cost-effective and outpatient-friendly setting. These centers are increasingly implementing EBUS to handle routine lung evaluations without the extended stays and higher overhead costs associated with hospitals. ASCs appeal to both providers and patients seeking efficiency and accessibility.

Cancer Specialty Clinics
Cancer specialty clinics represent close to 18% of the market, focusing heavily on lung cancer diagnostics, risk stratification, and biopsy-led staging. With growing adoption of precision oncology, these centers are turning to EBUS as a non-surgical, high-yield technique for sampling mediastinal masses. Their targeted care models make them well-suited for rapid EBUS integration.

Diagnostics Centers
Diagnostics centers make up about 12% of the market, providing referral-based bronchoscopy and ultrasound-guided biopsy services. As the demand for non-invasive outpatient diagnostics grows, these facilities are equipping themselves with compact EBUS systems to support pulmonologists, oncologists, and pathologists in shared care environments.

Global Endobronchial Ultrasound Biopsy Market, Segmentation by Geography

In this report, the Global Endobronchial Ultrasound Biopsy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Global Endobronchial Ultrasound Biopsy Market Share (%), by Geographical Region, 2024

North America
North America leads the global endobronchial ultrasound biopsy market with an estimated 42% share. The region benefits from a high rate of lung cancer screening, a mature healthcare reimbursement landscape, and early adoption of EBUS-TBNA technologies. Major hospitals and cancer centers in the U.S. and Canada are equipped with cutting-edge bronchoscopy systems, making this region a hub for advanced pulmonary diagnostics.

Europe
Europe contributes roughly 28% to the global market, driven by its strong network of public health systems, growing focus on oncology innovations, and robust support for early cancer detection programs. Leading countries including Germany and the UK are implementing clinical guidelines that emphasize EBUS use for accurate lymph node staging and tissue diagnosis.

Asia Pacific
Asia Pacific holds about 20% of the market and is expanding rapidly due to increasing lung cancer incidence, urban healthcare expansion, and growing access to specialized respiratory care. Regional governments are investing in hospital infrastructure, while local manufacturers and international collaborations are making EBUS more accessible in both urban and rural settings.

Middle East & Africa
Middle East & Africa accounts for approximately 6% of the EBUS biopsy market. Countries like Saudi Arabia and the UAE are leading investments in pulmonary diagnostics, while partnerships with global device suppliers are introducing EBUS training and technology transfer across the region. Efforts to reduce lung disease burdens are contributing to steady market growth.

Latin America
Latin America makes up around 4% of the global market. The region is gradually integrating bronchoscopic biopsy tools into public health systems, particularly in Brazil and Mexico. As awareness of minimally invasive cancer diagnostics grows and more pulmonologists are trained in EBUS techniques, the regional market is expected to gain momentum.